July 16, 2024Open Access

Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF-kB signaling pathway

Key Points

Key points are not available for this paper at this time.

Abstract

Parthenolide (PTL), a sesquiterpene lactone derived from the medicinal herb Chrysanthemum parthenium, exhibits various biological effects by targeting NF-kB, STAT3, and other pathways. It has emerged as a promising adjunct therapy for multiple malignancies.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Cai et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6012eb6db643587594d78 https://doi.org/https://doi.org/10.5306/wjco.v15.i7.895

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Smad4 re-expression increases the sensitivity to parthenolide in colorectal cancer2017 · 4 citations
2Theabrownin Inhibits Cell Cycle Progression and Tumor Growth of Lung Carcinoma through c-myc-Related Mechanism2017 · 52 citations
3NF-κB: a new player in angiostatic therapy2008 · 123 citations
4Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy2015 · 121 citations
5Angiogenesis as a hallmark of solid tumors - clinical perspectives2021 · 259 citations

Bookmark

View Full Paper